Rumagard-T 562.50 mg Injection
Ceftriaxone 500 mg + Tazobactam 62.5 mg Injection
| Composition | Ceftriaxone 500 mg + Tazobactam 62.5 mg |
|---|---|
| Dosage Form | Injection (Vial) |
| Pack Type | Vial + Diluent |
| Pack Size | 1 Vial Pack |
| MRP | ₹ 98.45 |
| Therapy | G.P. / Surgery — Cephalosporin + Tazobactam (Intermediate) |
| Storage | Store 2–25 °C, protect from light. |
📱 WhatsApp Enquiry📞 Call: +919041677932
About Rumagard-T 562.50 mg Injection
Rumagard-T 562.50 mg Injection provides Ceftriaxone 500 mg + Tazobactam 62.5 mg — intermediate strength for ESBL coverage at lower adult dose.
Manufactured by Trumac Healthcare under WHO-GMP. Available for monopoly-based PCD pharma franchise and third-party manufacturing.
Indications
- Mild-moderate infections with ESBL coverage
- Step-down ESBL therapy
Mechanism of Action
Ceftriaxone is a third-generation cephalosporin with broad gram-negative and gram-positive activity — binds penicillin-binding proteins (PBPs) inhibiting cell wall synthesis. Once-daily dosing due to long half-life (~8 hours). Penetrates CSF effectively making it first-line for meningitis. Tazobactam is a beta-lactamase inhibitor with broader spectrum than sulbactam — protects Ceftriaxone from extended-spectrum beta-lactamases (ESBL).
Dosage & Administration
Adults: 562.50 mg twice daily.
Side Effects
GI upset, diarrhoea (C. difficile risk), hypersensitivity (cross-reactivity with penicillins ~5%), biliary sludging (especially with calcium-containing IV fluids in neonates), rare haemolytic anaemia.
Contraindications & Precautions
Cephalosporin/penicillin hypersensitivity, neonates with hyperbilirubinaemia, concurrent calcium IV in neonates (Ringer's lactate).
Storage
Store 2–25 °C, protect from light.
Rumagard-T 562.50 mg Injection is available for monopoly-based PCD pharma franchise across India and for third-party manufacturing under your brand. WHO-GMP certified, with full visual-aid and promotional support. Become a Trumac franchise partner →
Frequently Asked Questions
What is Rumagard-T 562.50 mg Injection used for?
Rumagard-T 562.50 mg Injection contains Ceftriaxone 500 mg + Tazobactam 62.5 mg. Used as per the indications described above.
How should Rumagard-T 562.50 mg Injection be taken?
As directed by your physician. Complete the prescribed course.
Is Rumagard-T 562.50 mg Injection available for PCD pharma franchise?
Yes, Trumac Healthcare offers Rumagard-T 562.50 mg Injection on monopoly-based PCD pharma franchise and for third-party manufacturing.
How should Rumagard-T 562.50 mg Injection be stored?
Store below 30 °C in a dry place, protected from light and moisture.
Is Rumagard-T 562.50 mg Injection WHO-GMP certified?
Yes, manufactured in WHO-GMP and DCGI-compliant facilities.
Related Products
- Rumagard-T 1.125 gm Injection — Ceftriaxone 1000 mg + Tazobactam 125 mg
- Rumagard-T 281.25 mg Injection — Ceftriaxone 250 mg + Tazobactam 31.25 mg